CryoCinch Transcatheter Annuloplasty System
Mitral Valve Regurgitation and Tricuspid Valve Regurgitation
Pre-clinical/FeasibilityActive
Key Facts
Indication
Mitral Valve Regurgitation and Tricuspid Valve Regurgitation
Phase
Pre-clinical/Feasibility
Status
Active
Company
About Meacor
Meacor is an early-stage cardiovascular device innovator targeting the large unmet need in mitral and tricuspid valve regurgitation. The company's core technology is the CryoCinch system, which utilizes a proprietary cryoadhesion technique for anchor placement in a beating heart to perform a transcatheter annuloplasty. With a strong academic foundation from McGill University and experienced leadership, Meacor is positioned to advance a potentially disruptive platform for structural heart disease, though it remains pre-revenue with its device in the investigational stage.
View full company profile